REFEREE REPORTS
Referee #1:
In this study, Lightfoot and colleagues report about the ability of the S-layer glycoprotein SlpA of the GI/probiotic species Lactobacillus acidophilus (La) to protect against experimental colitis in mice through interaction with the C-type lectin receptor SignR3 (homolog to human DC-SIGN). Specifically, using a recombinant strain of La that expresses SlpA only (but not SlpB, SlpX and lipotechoic acid) or purified SlpA, the authors show in two models of T cell-and chemical-induced colitis that: -SlpA induces the recruitment of regulatory T cells and impairs the recruitment of pathogenic Th1 and Th17 cells in the colon; -SlpA ameliorates disease in term of tissue pathology, body weight, colitis-associated diarrhea, and impairs local production of inflammatory mediators, such as IL-1b and TNF; -The GI microbiota is shifted towards more Bacteroidetes and less Verrucomicrobia in treated mice, which translates into healthier epithelia (as measured by tight junction proteins for example); -Among the 8 DC-SIGN homologs, only SignR1 and SignR3 are induced in the colon of La-SlpA treated mice; -SlpA binds SignR3, but not SignR1; -Production of inflammatory mediators (e.g. IL-1b) and recruitment of Tregs is dysregulated in La/SlpA-treated SignR3-null mice; -Accordingly, the ability of La/SlpA to protect against experimental colitis is lost in SignR3-null mice, which translates into increased pathology and increased recruitment of neutrophils, IL-1b-producing DCs and macrophages and pathogenic RORgt+FoxP3+CD4+ Tregs in the colon.
Comments:
The paper is excellently written and easy to follow; the experiments have been designed appropriately together with appropriate controls and the overall dataset is most convincing. The overall message will be of high interest for a large audience, ranging from immunologists interested in innate immunity and inflammation to those interested in probiotics-mediated treatment of IBD and other inflammatory disorders.
I have no further (even minor) comment that could help further improving the manuscript.
Referee #2:
This is an interesting study in which it is a profound tolerizing effect of the interaction between SIGNR3 with SlpA in inflammatory bowel disease. The interaction with SlpA has strong influence on the induction of Treg, antiinflammatory phenotype of T cells, also alters composition of microbiota, and intestinal barrier function. The SlpA has shown to have this strong potential. The experimental setups are very solid for the proof if this molecular interaction with it functional consequences. The only thing I miss is in the discussion to link to the human setting, what molecules systems may give similar effects. Do they think that DC-SIGN has similar tolerogenic potential in the gut? Moreover the authors should explain a little bit more on the different SIGNR molecules and why they think that only SIGNR3 is involved in the interaction with SlpA. Is this due to same glycan specificity as DC-SIGN. Might also other Signs be involved, how is it with the expression of others Signs in the gut.
Referee #3:
The manuscript submitted by Lightfoot and colleagues describes experiments identifying bacterial strains that modulate host immunoregulatory signals to maintain gut homeostasis. An engineered Lactobacillus acidophilus, strain NCK2187 expressing only SlpA protects against gut inflammation in a murine model of induced colitis through its interaction with the C-type lectin, SIGNR3. The study demonstrates that SlpA binding to SIGNR3 dampens mucosal inflammation and reduces dysbiosis in the setting of a T cell transfer model of colitis in mice.
General Comments:
1. An isogenic mutant strain deficient only in SlpA should be employed as a negative control in all of the experiments. 2. To support the generalizability of the observations, other widely employed and reproducible animal model of gut inflammation should be tested. The effects of SlpA delivery by NCK2187 in an infectious murine model of colitis would be relevant. 3. The potential significance of the findings relates to using such a genetically engineered L. acidophilus strain to regulate host immune responses in human inflammatory diseases, such as Crohn's disease and ulcerative colitis. To demonstrate the relevance of SlpA binding to a C-lectin receptor in human disease, the human counterpart should be expressed in mammalian cells and in the murine gut to show whether SlpA also binds to DC-SIGN (Int Immunol 20001; 13:1293-90 ).
Specific Comments: 1. Figure Figure 6A: for consistency, the results of the untreated and PBS groups should be included. Statistical differences and P values should be indicated on the graph presenting changes in body weight and panel F. The day on which colonoscopies were performed should be indicated in the legend for panel D. 10. Figure 7A : statistical differences and P values should be provided for the various study groups presented. 11. Page 8, line 11: the word "cannot" should be replaced with "does not". 12. Expanded view Figure 1: The primer sequences for Ltb4r1 should be included in expanded view Table 6 . 13. Expanded view Figure 1B : A legend should be included, with an indication that gene expression is relative to the untreated, control group. Referee #1:
In this study, Lightfoot and colleagues report about the ability of the S-layer glycoprotein SlpA of the GI/probiotic species Lactobacillus acidophilus (La) to protect against experimental colitis in mice through interaction with the C-type lectin receptor SignR3 (homolog to human DC-SIGN). Specifically, using a recombinant strain of La that expresses SlpA only (but not SlpB, SlpX and lipotechoic acid) or purified SlpA, the authors show in two models of T cell-and chemical-induced colitis that: -SlpA induces the recruitment of regulatory T cells (IL-10-and TGF-b-expressing FoxP3+CD4+ Tregs) and impairs the recruitment of pathogenic Th1 and Th17 cells in the colon; -SlpA ameliorates disease in term of tissue pathology, body weight, colitis-associated diarrhea, and impairs local production of inflammatory mediators, such as IL-1b and TNF; -The GI microbiota is shifted towards more Bacteroidetes and less Verrucomicrobia in treated mice, which translates into healthier epithelia (as measured by tight junction proteins for example); -Among the 8 DC-SIGN homologs, only SignR1 and SignR3 are induced in the colon of La-SlpA treated mice; -SlpA binds SignR3, but not SignR1; -Production of inflammatory mediators (e.g. IL-1b) and recruitment of Tregs is dysregulated in La/SlpA-treated SignR3-null mice; -Accordingly, the ability of La/SlpA to protect against experimental colitis is lost in SignR3-null mice, which translates into increased pathology and increased recruitment of neutrophils, IL-1b-producing DCs and macrophages and pathogenic RORgt+FoxP3+CD4+ Tregs in the colon.
Comments:
We are deeply grateful for the comments and complements regarding our manuscript. Such encouraging comments sustain our efforts to continue our mechanistic work, which may result in a potential therapeutic platform. Humbly, thank you!
Referee #2:
We greatly appreciate all of the comments we have received from this highly respected reviewer. Accordingly, we have followed his advice and added more information regarding the aforementioned subject. In our revised manuscript, we demonstrate that CHO cells expressing human DC-SIGN bind to SlpA-coated beads, which is a human analogue of SIGNR3 (Fig. 5) , as requested by the reviewer. This interaction suggests that our responses induced via SIGNR3 binding might promote similar regulatory responses in humans through DC-SIGN, likely due to the same glycan specificity.
Referee #3:
The manuscript submitted by Lightfoot and colleagues describes experiments identifying bacterial strains that modulate host immunoregulatory signals to maintain gut homeostasis. An engineered Lactobacillus acidophilus, strain NCK2187 expressing only SlpA protects against gut inflammation in a murine model of induced colitis through its interaction with the C-type lectin, SIGNR3. The study demonstrates that SlpA binding to SIGNR3 dampens mucosal inflammation and reduces dysbiosis in the setting of a T cell transfer model of colitis in mice. 2. To support the generalizability of the observations, other widely employed and reproducible animal model of gut inflammation should be tested. The effects of SlpA delivery by NCK2187 in an infectious murine model of colitis would be relevant.
Response: We believe we have provided sufficient evidence using the two animal models previously presented to highlight the ability of NCK2187 and its purified SlpA to induce immune regulation, resulting in the amelioration of colonic disorders (e.g., colitis). Nonetheless, we now also provide new data dealing with the Citrobacter rodentium infection model that generally demonstrates the same trend of the regulatory role of NCK2187-SlpA. We hope that this will be sufficient to satisfy the high expectations of this highly respected reviewer.
3. The potential significance of the findings relates to using such a genetically engineered L. acidophilus strain to regulate host immune responses in human inflammatory diseases, such as Crohn's disease and ulcerative colitis. To demonstrate the relevance of SlpA binding to a C-lectin receptor in human disease, the human counterpart should be expressed in mammalian cells and in the murine gut to show whether SlpA also binds to DC-SIGN (Int Immunol 20001; 13:1293-90) . 4. Figure 4A : for clarity, it should be indicated that gene expression is relative to the untreated, control group. Response: Sure! This information has been included in the figure legend.
5. Figures 5C and D : purified SlpA should be tested and the data included here. Response: As in other steady-state studies (see figure 2), purified SlpA was not included, instead, this additional control group was reserved for the disease models employed herein, as they were deemed more significant to demonstrate its immunomodulatory role.
6. Figure 9. Figure 6A: for consistency, the results of the untreated and PBS groups should be included.
Statistical differences and P values should be indicated on the graph presenting changes in body weight and panel F. The day on which colonoscopies were performed should be indicated in the legend for panel D.
Response: Of course! Thanks
The suggested changes to the Figure were made. The day when the colonoscopies were performed was included in the legend.
10. Figure 7A : statistical differences and P values should be provided for the various study groups presented.
Response: See expanded view table 6 for statistical differences among the treatment groups in WT mice. No differences were observed in KO mice as can be noted in the figure.
11. Page 8, line 11: the word "cannot" should be replaced with "does not". Response: Done! 12. Expanded view Figure 1: The primer sequences for Ltb4r1 should be included in expanded view Table 6 . Response: We apologize about that. The sequence is now included. Thanks! Figure 1B : A legend should be included, with an indication that gene expression is relative to the untreated, control group. Response: Sure! This information has been included in the figure legend.
Expanded view
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Thank you for submitting your revised manuscript to The EMBO Journal. Your study as now been re-reviewed by referee #3. As you can see below, this referee appreciates the added data provided and supports publication in The EMBO Journal. I am therefore very pleased to accept the manuscript for publication here.
